3Saaiq M, lqbal T. Report: Fatal toxic epidermal necrolysis induced by sodium valproate[J].Pak J Pharm Sci, 2013, 26(3):637-639.
4Hamed SA,Abdella MM. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine statu[J]. Epilepsy Res, 2009,86:32-41.
5FDA. FDA Drug Safety Communication: Children born to mothers who took valproate products while pregnant may have impaired cognitive development[EB/OL].(2011-06-30)[2011-07-01].http://www.fda.gov/Drugs/DrugSafety/ucm261543.htm.
6FDA. FDA information for healthcare professionals: risk of neural tube birth defects following prenatal exposure to valproate[EB/OL]. (2009-12-03)[2013-08-15].http://www.fda.gov/Drugs/DrugSafety/Postmarket DrugSafety Information for Patients and Providers /Drug Safety Information for Heath care Professionals/ucm192649.htm.
7Armon C, Brown E, Carwile S, et al. Sensorineural hearing loss: a reversible effect of valproic acid[J]. Neurology, 1990,40(12):1896-1898.
8Gosavi DD, Suman A, Jain M. Sodium valproate induced increased frequency of micturition and enuresis[J]. Indian J Pharmacol, 2013,45(1): 87-88.
9Stephens JR, Levy RH. Valproate hepatotoxicity syndrome: Hypotheses of pathogenesis[J]. Pharm Weekbl Sci, 1992,14(3A):118-121.
